Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Exelixis

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1994-01-01

Employees: 1.3K

Market Cap: $7.3B

Website: http://www.exelixis.com

Introduction: Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Clinical Trials

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Papillary Thyroid Cancer
Follicular Thyroid Cancer
Huerthle Cell Thyroid Cancer
Renal Cell Carcinoma

Interventions: Drug: rosiglitazone
Drug: XL184

First Posted Date: 2010-04-09

Last Posted Date: 2013-09-19

Lead Sponsor: Exelixis

Target Recruit Count: 40

Registration Number: NCT01100619

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States

and more 2 locations

Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Phase 2

Completed

Conditions: Astrocytic Tumors

Interventions: Drug: XL184

First Posted Date: 2010-02-15

Last Posted Date: 2014-07-30

Lead Sponsor: Exelixis

Target Recruit Count: 19

Registration Number: NCT01068782

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma
Gliosarcoma
Giant Cell Glioblastoma

Interventions: Drug: XL184
Drug: temozolomide
Radiation: Radiation Therapy

First Posted Date: 2009-08-17

Last Posted Date: 2014-09-22

Lead Sponsor: Exelixis

Target Recruit Count: 26

Registration Number: NCT00960492

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States

and more 5 locations

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Phase 2

Completed

Conditions: Solid Tumors
Cancer

Interventions: Drug: Cabozantinib
Drug: Placebo

First Posted Date: 2009-07-15

Last Posted Date: 2024-04-25

Lead Sponsor: Exelixis

Target Recruit Count: 730

Registration Number: NCT00940225

Locations: 🇺🇸
Pinnacle Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 34 locations

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: XL888

First Posted Date: 2008-11-24

Last Posted Date: 2015-08-21

Lead Sponsor: Exelixis

Target Recruit Count: 33

Registration Number: NCT00796484

Locations: 🇺🇸
Hospital of the University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Phase 3

Completed

Conditions: Thyroid Cancer

Interventions: Drug: XL184
Drug: Placebo

First Posted Date: 2008-06-25

Last Posted Date: 2021-04-20

Lead Sponsor: Exelixis

Target Recruit Count: 330

Registration Number: NCT00704730

Locations: 🇺🇸
University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
TGEN Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 46 locations

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Phase 1

Withdrawn

Conditions: Cancer
Non-small-cell Lung Cancer
Breast Cancer

Interventions: Drug: XL647
Drug: XL147

First Posted Date: 2008-06-24

Last Posted Date: 2015-08-20

Lead Sponsor: Exelixis

Registration Number: NCT00704392

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York City, New York, United States
🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: XL184

First Posted Date: 2008-06-24

Last Posted Date: 2024-02-05

Lead Sponsor: Exelixis

Target Recruit Count: 222

Registration Number: NCT00704288

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: XL184
Drug: erlotinib

First Posted Date: 2008-01-17

Last Posted Date: 2013-09-19

Lead Sponsor: Exelixis

Target Recruit Count: 92

Registration Number: NCT00596648

Locations: 🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
University of California, Davis, Sacramento, California, United States

and more 10 locations

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Phase 1

Terminated

Conditions: Polycythemia Vera

Interventions: Drug: XL019

First Posted Date: 2008-01-16

Last Posted Date: 2015-08-21

Lead Sponsor: Exelixis

Target Recruit Count: 3

Registration Number: NCT00595829

Locations: 🇺🇸
UCLA School of Medicine, Center for Health Sciences, Los Angeles, California, United States
🇺🇸
UCSF - Division of Hematology/Oncology, San Francisco, California, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy